Icon Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. All right. Hi, good afternoon, everybody. I'm Dave Windley with Jefferies Healthcare Equity Research in the States. I cover the CRO space. Pleased to have the ICON management team here with us. Pleased to have all of you in the audience and anybody listening in on the webcast as well. Thank you for your interest in Jefferies Healthcare Conference. We are proud of the growth that we have seen in the conference. Thank you to the ICON management team for joining us. Barry Balfe, the company's CEO, been in that seat for a little over a year, approaching a year?
Just over. Just over. Right.
Q3 of last year. But 20 years with the company, plus. And Nigel Clerkin, the company's CFO, who joined in 2024. Appreciate both of you being here. I think, Barry, you wanted to start off with a couple of comments, and then I've got some easy questions for you.
It wouldn't be like you if you did, Dave. Look, I'll be very brief, looking forward to the Q&A. I think we meet at an interesting time. There has been much commentary on the demand environment for drug development services in recent times, CRO services in particular. We're probably now in the fifth straight quarter of demonstrably improved demand environment, and thankfully, probably in the fourth or fifth straight quarter where I think ICON is outcompeting a peer set in terms of converting on that demand environment. We feel good about both of those dynamics. But it's also an interesting time as we continue to navigate the confluence of twin revolutions in technology and in biomedical science. It is not an exaggeration to say that we can literally sequence millions of times more molecules than was the case a generation ago.
The question is, how can companies like ourselves help pharma and biotech sponsors to make better bets and convert them to market or failure faster, more cost-effectively, and more predictably? A lot of what we have been talking about with our customers in the last year or so really talks about where ICON needs to sharpen its commercial focus to do just that and sharpen our strategic focus to do just that. It is often said that the CRO industry is poorly differentiated. While I agree that is largely true, it is also true that this is a company that seeks to differentiate in how we partner every bit as much as the capabilities that form the basis of those partnerships. We talk a lot with our customers about co-investment. We talk a lot with our customers about transformation.
We talk a lot with our customers about the need to put these emergent technologies in the hands of subject matter experts who know how to convert them into capability, into time, and into data insights rather than just data. I imagine, Dave, that is a lot of what we will be talking about here today. So I will pull up there, thank everybody for their attention, and submit myself to the inquisition.
All right. That is a good tee-up. So I do want to start with where you started on the demand environment and your outcompeting peers. So ICON's bookings have not just outpaced but well-outpaced peers for now four quarters, so much so that the market, I think, has questions about where is all that business coming from. So I would be very pleased for you to describe the factors that are helping to lift your book-to-bill from, as you have described, what was about a 1.0 in the two years ago period to what is now a 1.3 on a service fee basis in the trailing one-year period.
Yeah. I think the first thing to say is that the preceding period of a year or maybe even two years was the abnormality. Right now is better than a historical average, but that was much, much worse than a historical average. It is probably no secret to our attendees and listeners today that pharma went through a period of some hesitancy. We had biotech funding challenges, not just in raising capital but deploying them. We had large pharma deprioritizing out of certain areas with something of a lag before they reprioritized back into others. This was all set against the backdrop of IRA, MFN, and loss of exclusivity in relatively swift succession. It is fair to say that healthcare was too much on the front pages and not enough on the business pages and the healthcare pages of our newspapers. So I think some of this is right-sizing.
But it is also true that we came out in the first quarter of 2025, and we talked about certain areas where we were going to sharpen our focus. We are already alliance partners of 18 of the top 20 pharma companies, but I was pretty clear in February of 2025 that I did not think we were diversified enough within those accounts. There was an opportunity for us to partner in FSO and FSP and Labs and kitting and early phase and evidence generation and technology services and site networks rather than one or two of those services. And I am pleased to say we have seen good conversion on that. So alongside sustained, robust growth in our FSP business, I think the robustness of the large pharma full outsourcing trends in the last 18 months have perhaps been ahead of other people's expectations.
And unsurprisingly, given that ICON wins about two-thirds of what we touch in that space, that is an area where we have profited disproportionately. In the midsize segment, I think I am on record multiple times as having said I thought we were too transactional in our approach. We were working with these companies rather than partnering with them sufficiently strategically on a preferred partnership or alliance basis. And I do not think there has been a quarter since, correct me if I am wrong on this. I do not think there has been a quarter since in which we have not rolled up some of those transactional relationships into formalized alliance partnerships. That has certainly been a tailwind to the commercial performance. And in biotech, Dave, you and I have spoken many times. I did not feel that this company was seeing enough of that biotech market.
We are now engaged with 30% more biotech companies than we were just one year ago, and we saw a significant uptick in RFP flow. If RFP flow was up 7%-ish, high single digits across the business in the last 12 months, over the last 24 months, it is up substantially in biotech specifically. Still a bit to do on win rates in that space. You know, we win roughly consistently about one in four of the dollars we bid on rather than the one in three I think we should be winning or perhaps better. So there is more to do there. But I think you are really seeing the product of more benign environment, and superior execution, which to a significant degree is underpinned by some of the technology bets we have made.
And maybe I will just finish by saying it is okay, in fact, necessary to align ourselves with the large-scale transformational agenda that AI represents, but that is just a ticket to entry. In order to win, and especially to win disproportionately, we have to be able to produce innovation that creates value now. And we gave some examples of why we think that is resonating with customers in our most recent earnings call. To take 27%, 28% of the cycle times out of simple things like SDTM and programming cycle times is value today. To take 10 and then 20 and then 30% out of site contracting cycle times is value today. To be able to roll out monitoring agents and other agentic capabilities, put them in the hands of our teams to generate better data insights, make better decisions, and return better intelligence to our customers is generating value today.
And I think increasingly, we're seeing win rates being driven by not just alignment with longer-term transformation, but the ability of SMEs to turn commercially available tools into bespoke capability.
I want to drill in on a couple of these things. When you talk about conversations with these clients around co-investment and co-transformation, when you say co-investment, can you describe what you mean by that?
Well, a lot of the time, capital's finite everywhere, right? So we were very serious about saying that a lot of where we make our investments will be driven by where our customers have or would like to make theirs. So you go to a customer that's thinking about experimenting with a monitoring agent like Meridian that I just talked about, and you say, "Well, why don't you fund your next favorite bet, and we'll give you access to this, and that's capital that you can free up." In other cases, it's about saying, "Well, you could only fund your five favorite ideas. What was your sixth? Because maybe it aligns with our roadmap." So a lot of these large-scale partnerships will include a commitment to shared innovation, shared innovation dollars very often.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
